GlassScriptPhysician profile
Laura L Odom
NPI 1528436243
$1,476.74
in general payments reported to CMS, 2019-2025
21 companies · $86.46 in 2025
The $86.46 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $507 · 2023: $359 · 2024: $259 · 2025: $86.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.68 | 2021-2024 | |
| Novo Nordisk INC | $324.83 | 2021-2025 | Rybelsus, Ozempic |
| Alkermes, INC. | $164.34 | 2021-2023 | Lybalvi |
| Lilly USA, LLC | $163.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.96 | 2021-2022 | |
| Dexcom, INC. | $51.52 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.85 | 2024-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $36.17 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $34.49 | 2021-2024 | Vaxneuvance, Capvaxive, Vaxelis |
| Exact Sciences Corporation | $32.97 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $31.55 | 2021 | |
| Lundbeck LLC | $24.72 | 2023 | Rexulti |
| Amarin Pharma, INC. | $22.69 | 2022 | |
| Ironshore Pharmaceuticals INC. | $21.16 | 2023 | Jornay Pm |
| Agios Pharmaceuticals, INC. | $20.32 | 2025 | Pyrukynd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.61 | 2023 | Invega Trinza, Invega Sustenna |
| Pfizer INC. | $16.81 | 2022 | |
| Gilead Sciences, INC. | $15.73 | 2024 | |
| Seqirus USA INC | $15.34 | 2025 | Flucelvax, Fluad |
| Biohaven Pharmaceutical Holding Company LTD. | $13.60 | 2022 | |
| Mannkind Corporation | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.